A Novel Huntington’s Disease Assessment Platform to Support Future Drug Discovery and Development
Huntington’s disease (HD) is a lethal neurodegenerative disorder without efficient therapeutic options. The inefficient translation from preclinical and clinical research into clinical use is mainly attributed to the lack of (i) understanding of disease initiation, progression, and involved molecula...
Main Authors: | Jingyun Wu, Luisa Möhle, Thomas Brüning, Iván Eiriz, Muhammad Rafehi, Katja Stefan, Sven Marcel Stefan, Jens Pahnke |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-11-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/23/23/14763 |
Similar Items
-
An unsupervised computational pipeline identifies potential repurposable drugs to treat Huntington's disease and multiple sclerosis
by: Luca Menestrina, et al.
Published: (2022-12-01) -
Autonomic Changes in Juvenile-Onset Huntington’s Disease
by: Jordan L. Schultz, et al.
Published: (2020-08-01) -
Molecular Biology of Huntington’s Disease
by: Nagehan Ersoy, et al.
Published: (2005-02-01) -
How has CRISPR transformed therapeutic drug discovery?
by: Jade Parker
Published: (2023-03-01) -
Commentary: Acanthocytes identified in Huntington's disease
by: Kevin Peikert, et al.
Published: (2022-11-01)